Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 WuXi AppTec’s Lab Testing Division Expands in Suzhou | Contract Pharma
Breaking News

WuXi AppTec’s Lab Testing Division Expands in Suzhou

Increases toxicology capacity by 80% to execute full-service preclinical and clinical safety assessments for biologics and small molecules

WuXi AppTec’s Lab Testing Division (LTD) has expanded the Suzhou safety assessment facility by increasing toxicology capacity by 80% to meet global preclinical testing needs and to enable the acceleration of development timelines. With the expansion, the toxicology facility will cover an area of 580,000 square feet and execute full-service preclinical and clinical stage safety assessments for biologic and small molecule drugs.

“By investing in the toxicology facility, we are answering the call for increased safety assessment capacity for global customers,” said Dr. Steve Yang, executive vice president, chief business officer of WuXi AppTec. “WuXi AppTec LTD is committed to enabling our customers to advance the drug development process and bring new treatment to patients in need.”

The toxicology unit of WuXi AppTec LTD provides discovery, IND- and NDA-enabling studies for global customers. The unit has full AAALAC accreditation and has successfully passed inspections by the FDA, OECD, NMPA. LTD provides services from Shanghai, Nanjing, Suzhou facilities in China, as well as St. Paul, Atlanta, Plainsboro and Cranbury facilities in USA.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters